In a phase I-II trial(NCT03157128), selpercatinib showed durable efficacy in 19 patients with previously-treated RET fusion-positive thyroid cancer, and the response rate was 79% (95% CI, 54–94) (147). Here, RET is linked to thyroid cancer.